CD40 Ligand (CD40L)

Subscribe to Selected New Research on CD40 Ligand

1172 relevant articles (49 outcomes, 145 trials/studies) found for this Bio-Agent

Description: A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.

Also Known As:

CD40L; Antigen, CD154; CD154 Antigen; T-B Cell Activating Molecule; TNF Superfamily, Member 5; gp39 Antigen, T-Cell; T-Cell gp39 Antigen; gp39 Antigen, T Cell; Antigens, CD154; CD154 Antigens; Tumor Necrosis Factor Ligand Superfamily Member 5

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lip, Gregory Y H: 7 articles (09/2008 - 06/2004)
2.	Libby, Peter: 6 articles (03/2007 - 01/2003)
3.	Violi, Francesco: 5 articles (06/2008 - 01/2005)
4.	Pignatelli, Pasquale: 5 articles (06/2008 - 01/2005)
5.	Loskog, Angelica: 5 articles (05/2008 - 06/2004)
6.	Aukrust, Pål: 5 articles (02/2008 - 01/2003)
7.	Schönbeck, Uwe: 5 articles (03/2007 - 01/2003)
8.	Ferro, Domenico: 4 articles (06/2008 - 01/2005)
9.	Loffredo, Lorenzo: 4 articles (06/2008 - 11/2006)
10.	Varo, Nerea: 4 articles (06/2008 - 01/2003)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2008 - "CD40/CD40L signaling promotes both B cell and CTL responses in vivo, the latter being beneficial in tumor models. " 11/01/1997 - "Mice injected with cells that expressed CD40L had a significant reduction in average tumor size as compared to controls (p < 0.0001). " 02/01/1997 - "The understanding of the biology of CD40L has improved our diagnostic and therapeutic repertoire in the management of several human diseases, including CD40+ tumors." 06/01/2005 - "In conclusion, we provide evidence that CD40L/IRIV, by acting through the CD40L/CD40 signaling pathway, acts as an immune-adjuvant that could increase the efficacy of a CEA-specific cancer vaccine, which could provide an efficacious new strategy for cancer therapy." 02/01/2002 - "In the present study, we investigated the efficacy of antitumor immunity induced by vaccination with DCs engineered to express CD40L and pulsed with Mut1 tumor peptide. " Order ALL the reference details at left...
2.	Infection 04/20/1998 - "To study the role of CD40L in mediating protection against infection with H. " 10/01/2005 - "Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection." 01/01/2007 - "This article reviews current studies of the potential role of CD40/CD40L interaction in the modulation of immune responses against some protozoan parasites and highlights recent developments regarding manipulation of this interaction for promoting control of parasite infections." 10/01/2005 - "cruzi with the murine CD40L gene and to study the consequences of this transfection on the course of infection. " 03/01/2003 - "Although previous studies demonstrated a requirement for CD40-CD40 ligand (CD40L) interaction in the development of resistance to Leishmania infection, we recently showed that mice lacking the gene for CD40L (CD40L(-/-) mice) can control Leishmania major infection when they are infected with reduced numbers of parasites. " Order ALL the reference details at left...
3.	Inflammation 07/01/2006 - "Recent studies have demonstrated that PLTs promote immunity and inflammation mainly by means of the CD40/CD40L pathway. " 02/01/2006 - "Recent studies suggest that CD40-CD40 ligand (CD40L) system is proven to be an important mediator of several auto-immune and chronic inflammation diseases. " 01/01/2006 - "The aim of the study was estimation of a concentration soluble form of CD40, CD40L (CD154) in the bacterial and viral inflammation of the central nervous system in two compartments - blood circulation and intrathecally, before and after the treatment. " 01/01/2003 - "These data provide novel insight into the mechanism through which elevated levels of soluble CD40 ligand may reflect cardiovascular risk in humans and illustrate the potential value of interfacing high-resolution MRI with studies of vascular inflammation." 08/18/2009 - "The CD40/CD40 ligand system: linking inflammation with atherothrombosis." Order ALL the reference details at left...
4.	Atherosclerosis (Atheroma) 10/01/2005 - "OBJECTIVE: The purpose of this study was to evaluate the associations between plasma levels of soluble CD40 ligand (sCD40L), atherosclerosis risk factors, and evidence of subclinical atherosclerosis. " 10/01/2005 - "Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study." 01/01/2003 - "Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI." 10/01/1998 - "We also discuss new studies that reveal how CD40 ligand and certain other stimuli can promote chemokine expression in atherosclerosis." 08/01/2009 - "Moreover, recent progress indicates the involvement of neutrophil CD40, platelet CD40L and dendritic cell CD40 in atherogenesis. " Order ALL the reference details at left...
5.	Adenocarcinoma 03/01/2008 - "METHODS: The efficacy of CD40L gene transfer in initiating anti-tumour immune response was investigated in a pancreatic ductal adenocarcinoma orthotopic syngeneic mouse model. " 03/01/2008 - "Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma." 04/01/1999 - "Constitutive CD40 expression, but not that of CD40L, was slightly detectable on normal human bronchial epithelial cells (HBEC) in situ and on an adult lung adenocarcinoma (SKLU1) cell line, while another cell line, a bronchial transformed SV40 cell line (WI26VA4), was negative for CD40. " 06/01/2006 - "We investigated the anti-tumor effects induced by CD40L gene transfer into the mouse prostate adenocarcinoma cell line TRAMP-C2, both in vitro and in vivo. " 11/15/2002 - "To this end, the antitumor activity of SLC and CD40L expressed singly or in combination using the herpes simplex virus (HSV)-derived amplicon was examined in two murine models: A20, a B-cell lymphoma, and CT-26, an adenocarcinoma. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	CD40 Ligand (CD40L)
2.	Antigens
3.	C-Reactive Protein
4.	Interleukin-12 (IL 12)
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Interleukin-4 (Interleukin 4)
7.	P-Selectin
8.	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
9.	Interleukin-6 (Interleukin 6)
10.	Cytokines

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Subcutaneous Injections
4.	Bariatric Surgery
5.	Stem Cell Transplantation

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>